Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$0.37 +3.4%	$0.38	$0.30 ▼ $1.34	$13.73M	0.96	173,100 shs	51,399 shs
FBIO Fortress Biotech	$1.65 -2.4%	$1.62	$1.33 ▼ $2.89	$48.79M	1.85	406,936 shs	154,254 shs
SPPI Spectrum Pharmaceuticals	$1.03	$1.01	$0.32 ▼ $1.57	$211.41M	2.15	1.93 million shs	N/A
VSTM Verastem	$7.29 +1.7%	$6.38	$2.10 ▼ $13.52	$375.36M	0.85	1.08 million shs	2.11 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	0.00%	+2.40%	+11.83%	-22.15%	-71.27%
FBIO Fortress Biotech	0.00%	-7.65%	+15.75%	-3.43%	+1.20%
SPPI Spectrum Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
VSTM Verastem	0.00%	-3.50%	+54.53%	+25.79%	-39.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BOLT Bolt Biotherapeutics	2.4884 of 5 stars	3.0	3.0	0.0	0.0	2.7	1.7	1.3
FBIO Fortress Biotech	1.9942 of 5 stars	3.5	0.0	0.0	0.0	1.9	3.3	0.6
SPPI Spectrum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	3.1905 of 5 stars	4.5	1.0	0.0	0.0	3.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLT Bolt Biotherapeutics	2.00	Hold	$1.13	204.05% Upside
FBIO Fortress Biotech	3.00	Buy	$21.00	1,172.73% Upside
SPPI Spectrum Pharmaceuticals	0.00	N/A	N/A	N/A
VSTM Verastem	3.00	Buy	$14.33	96.62% Upside

Current Analyst Ratings Breakdown

Latest FBIO, VSTM, BOLT, and SPPI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
4/10/2025	VSTM Verastem	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/9/2025	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
3/25/2025	BOLT Bolt Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/25/2025	BOLT Bolt Biotherapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$1.50 ➝ $1.25
3/24/2025	VSTM Verastem	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $14.00
3/24/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
3/21/2025	VSTM Verastem	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
3/11/2025	FBIO Fortress Biotech	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $16.00

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLT Bolt Biotherapeutics	$7.69M	1.84	N/A	N/A	$2.97 per share	0.12
FBIO Fortress Biotech	$57.68M	0.85	N/A	N/A	$0.10 per share	16.50
SPPI Spectrum Pharmaceuticals	$10.11M	20.91	N/A	N/A	$0.15 per share	6.87
VSTM Verastem	$10M	37.54	N/A	N/A	$2.27 per share	3.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLT Bolt Biotherapeutics	-$69.20M	-$1.66	N/A	N/A	N/A	-665.56%	-69.46%	-48.55%	5/13/2025 (Estimated)
FBIO Fortress Biotech	-$60.64M	-$2.78	N/A	N/A	N/A	-84.53%	N/A	-34.93%	5/13/2025 (Estimated)
SPPI Spectrum Pharmaceuticals	-$75.40M	-$0.36	N/A	14.71	N/A	N/A	-218.44%	-66.16%	N/A
VSTM Verastem	-$87.37M	-$3.50	N/A	N/A	N/A	N/A	-332.73%	-73.97%	N/A

Latest FBIO, VSTM, BOLT, and SPPI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	FBIO Fortress Biotech	-$0.44	N/A	N/A	N/A	$11.62 million	N/A
5/13/2025	Q1 2025	BOLT Bolt Biotherapeutics	-$0.34	-$0.29	+$0.05	-$0.29	$0.77 million	N/A
3/31/2025	Q4 2024	FBIO Fortress Biotech	-$0.79	-$0.26	+$0.53	-$0.26	$16.30 million	$15.12 million
3/24/2025	Q4 2024	BOLT Bolt Biotherapeutics	-$0.38	-$0.38	N/A	-$0.42	$0.79 million	$0.01 million
3/20/2025	Q4 2024	VSTM Verastem	-$0.76	-$1.33	-$0.57	-$1.33	$0.15 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLT Bolt Biotherapeutics	$0.36	97.30%	N/A	N/A	N/A
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
SPPI Spectrum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLT Bolt Biotherapeutics	0.21	3.16	3.16
FBIO Fortress Biotech	N/A	1.23	1.06
SPPI Spectrum Pharmaceuticals	N/A	2.71	2.38
VSTM Verastem	2.77	3.23	3.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLT Bolt Biotherapeutics	86.70%
FBIO Fortress Biotech	96.51%
SPPI Spectrum Pharmaceuticals	21.67%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
BOLT Bolt Biotherapeutics	6.10%
FBIO Fortress Biotech	33.40%
SPPI Spectrum Pharmaceuticals	2.70%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLT Bolt Biotherapeutics	90	38.34 million	26.45 million	Not Optionable
FBIO Fortress Biotech	170	29.57 million	18.39 million	Optionable
SPPI Spectrum Pharmaceuticals	86	205.25 million	199.70 million	Optionable
VSTM Verastem	50	51.49 million	43.53 million	Optionable

FBIO, VSTM, BOLT, and SPPI Headlines

Recent News About These Companies

FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type

May 12 at 6:29 PM | pmlive.com

Brokerages Set Verastem, Inc. (NASDAQ:VSTM) Target Price at $13.89

May 12 at 2:13 AM | americanbankingnews.com

Verastem (NASDAQ:VSTM) Given New $14.00 Price Target at HC Wainwright

May 11 at 9:16 AM | marketbeat.com

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by Brokerages

May 11 at 2:28 AM | marketbeat.com

Balyasny Asset Management L.P. Makes New $20.40 Million Investment in Verastem, Inc. (NASDAQ:VSTM)

May 10 at 5:20 AM | marketbeat.com

Verastem Target of Unusually High Options Trading (NASDAQ:VSTM)

May 10 at 1:29 AM | americanbankingnews.com

FDA Grants Accelerated Approval to Verastem Oncology’s Avmapki Fakzynja Co-Pack for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

May 9 at 6:32 PM | pharmexec.com

High-graded low-grade ovarian duo wins for Verastem at FDA

May 9 at 6:32 PM | bioworld.com

Verastem Oncology Cancer Drug Combination Gets FDA Approval

May 9 at 1:31 PM | marketwatch.com

Verastem scores FDA nod for first-of-its-kind oral combination to treat rare form of ovarian cancer

May 9 at 1:31 PM | fiercepharma.com

Verastem (VSTM) Sees Price Target Increase and FDA Approval Boost | VSTM Stock News

May 9 at 10:31 AM | gurufocus.com

FDA nod for first-ever treatment for LGSOC, a rare cancer

May 9 at 8:30 AM | thepharmaletter.com

US FDA approves Verastem's ovarian cancer therapy

May 9 at 8:30 AM | msn.com

Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update

May 8, 2025 | marketwatch.com

FDA Approves Verastem's Avmapki, Fakzynja Combo for KRAS-Mutant Ovarian Cancer Patients

May 8, 2025 | precisionmedicineonline.com

Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased

May 8, 2025 | msn.com

FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer

May 8, 2025 | benzinga.com

Verastem’s Breakthrough FDA Approval and Market Potential for KRAS Mutant LGSOC Therapy

May 8, 2025 | tipranks.com

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025 | businesswire.com

U.S. FDA approves Verastem's cancer therapy

May 8, 2025 | reuters.com

Susquehanna Fundamental Investments LLC Buys New Shares in Verastem, Inc. (NASDAQ:VSTM)

May 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, FBIO, BOLT, and SPPI Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

$0.37 +0.01 (+3.35%)

Closing price 03:55 PM Eastern

Extended Trading

$0.38 +0.01 (+1.62%)

As of 07:50 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Fortress Biotech NASDAQ:FBIO

$1.65 -0.04 (-2.37%)

Closing price 04:00 PM Eastern

Extended Trading

$1.69 +0.04 (+2.67%)

As of 07:57 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

Verastem NASDAQ:VSTM

$7.29 +0.12 (+1.67%)

Closing price 04:00 PM Eastern

Extended Trading

$7.22 -0.07 (-0.96%)

As of 07:46 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time